vs
NATIONAL RESEARCH CORP（NRC）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
NATIONAL RESEARCH CORP的季度营收约是REGENXBIO Inc.的1.2倍（$35.2M vs $30.3M），NATIONAL RESEARCH CORP净利率更高（5.1% vs -221.3%，领先226.4%），REGENXBIO Inc.同比增速更快（43.0% vs -4.6%），NATIONAL RESEARCH CORP自由现金流更多（$6.1M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -0.2%）
NRC Health（原国家研究公司）是一家美国医疗健康企业，1981年成立，总部位于内布拉斯加州林肯市。公司主要在美加两国提供医疗健康相关产品及订阅式解决方案，深耕区域医疗健康服务领域。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
NRC vs RGNX — 直观对比
营收规模更大
NRC
是对方的1.2倍
$30.3M
营收增速更快
RGNX
高出47.6%
-4.6%
净利率更高
NRC
高出226.4%
-221.3%
自由现金流更多
NRC
多$58.9M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-0.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $35.2M | $30.3M |
| 净利润 | $1.8M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 13.3% | -190.0% |
| 净利率 | 5.1% | -221.3% |
| 营收同比 | -4.6% | 43.0% |
| 净利润同比 | -72.6% | -31.2% |
| 每股收益（稀释后） | $49.58 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NRCRGNX
| Q4 25 | $35.2M | $30.3M | ||
| Q3 25 | $34.6M | $29.7M | ||
| Q2 25 | $34.0M | $21.4M | ||
| Q1 25 | $33.6M | $89.0M | ||
| Q4 24 | $36.9M | $21.2M | ||
| Q3 24 | $35.8M | $24.2M | ||
| Q2 24 | $35.0M | $22.3M | ||
| Q1 24 | $35.3M | $15.6M |
净利润NRCRGNX
| Q4 25 | $1.8M | $-67.1M | ||
| Q3 25 | $4.1M | $-61.9M | ||
| Q2 25 | $-106.0K | $-70.9M | ||
| Q1 25 | $5.8M | $6.1M | ||
| Q4 24 | $6.6M | $-51.2M | ||
| Q3 24 | $5.7M | $-59.6M | ||
| Q2 24 | $6.2M | $-53.0M | ||
| Q1 24 | $6.4M | $-63.3M |
毛利率NRCRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率NRCRGNX
| Q4 25 | 13.3% | -190.0% | ||
| Q3 25 | 22.4% | -176.3% | ||
| Q2 25 | 4.7% | -296.3% | ||
| Q1 25 | 25.6% | 13.6% | ||
| Q4 24 | 26.0% | -242.1% | ||
| Q3 24 | 22.3% | -256.6% | ||
| Q2 24 | 25.3% | -251.3% | ||
| Q1 24 | 24.8% | -408.8% |
净利率NRCRGNX
| Q4 25 | 5.1% | -221.3% | ||
| Q3 25 | 11.9% | -208.3% | ||
| Q2 25 | -0.3% | -331.8% | ||
| Q1 25 | 17.2% | 6.8% | ||
| Q4 24 | 17.8% | -241.3% | ||
| Q3 24 | 15.9% | -246.3% | ||
| Q2 24 | 17.6% | -237.7% | ||
| Q1 24 | 18.0% | -405.4% |
每股收益（稀释后）NRCRGNX
| Q4 25 | $49.58 | $-1.30 | ||
| Q3 25 | $0.18 | $-1.20 | ||
| Q2 25 | $-0.01 | $-1.38 | ||
| Q1 25 | $0.25 | $0.12 | ||
| Q4 24 | $0.27 | $-0.99 | ||
| Q3 24 | $0.24 | $-1.17 | ||
| Q2 24 | $0.26 | $-1.05 | ||
| Q1 24 | $0.27 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.1M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $14.0M | $102.7M |
| 总资产 | $134.9M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NRCRGNX
| Q4 25 | $4.1M | $230.1M | ||
| Q3 25 | $2.2M | $274.2M | ||
| Q2 25 | $5.3M | $323.3M | ||
| Q1 25 | $2.5M | $267.9M | ||
| Q4 24 | $4.2M | $234.7M | ||
| Q3 24 | $3.5M | $255.5M | ||
| Q2 24 | $485.0K | $290.4M | ||
| Q1 24 | $1.7M | $338.7M |
总债务NRCRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $48.7M | — | ||
| Q2 24 | $33.3M | — | ||
| Q1 24 | $35.2M | — |
股东权益NRCRGNX
| Q4 25 | $14.0M | $102.7M | ||
| Q3 25 | $14.3M | $161.5M | ||
| Q2 25 | $21.3M | $213.7M | ||
| Q1 25 | $29.7M | $274.2M | ||
| Q4 24 | $31.3M | $259.7M | ||
| Q3 24 | $34.6M | $301.4M | ||
| Q2 24 | $40.2M | $348.3M | ||
| Q1 24 | $36.9M | $390.7M |
总资产NRCRGNX
| Q4 25 | $134.9M | $453.0M | ||
| Q3 25 | $135.7M | $525.2M | ||
| Q2 25 | $141.4M | $581.0M | ||
| Q1 25 | $135.2M | $490.9M | ||
| Q4 24 | $132.5M | $466.0M | ||
| Q3 24 | $131.8M | $519.1M | ||
| Q2 24 | $119.1M | $569.4M | ||
| Q1 24 | $120.9M | $629.2M |
负债/权益比NRCRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.41× | — | ||
| Q2 24 | 0.83× | — | ||
| Q1 24 | 0.95× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $7.2M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $6.1M | $-52.8M |
| 自由现金流率自由现金流/营收 | 17.2% | -174.0% |
| 资本支出强度资本支出/营收 | 3.2% | 1.7% |
| 现金转化率经营现金流/净利润 | 3.99× | — |
| 过去12个月自由现金流最近4个季度 | $15.7M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流NRCRGNX
| Q4 25 | $7.2M | $-52.3M | ||
| Q3 25 | $13.8M | $-56.0M | ||
| Q2 25 | $-1.1M | $-49.3M | ||
| Q1 25 | $6.6M | $33.6M | ||
| Q4 24 | $6.4M | $-31.6M | ||
| Q3 24 | $9.4M | $-40.5M | ||
| Q2 24 | $6.8M | $-45.5M | ||
| Q1 24 | $12.0M | $-55.5M |
自由现金流NRCRGNX
| Q4 25 | $6.1M | $-52.8M | ||
| Q3 25 | $10.2M | $-56.5M | ||
| Q2 25 | $-4.1M | $-49.7M | ||
| Q1 25 | $3.7M | $32.6M | ||
| Q4 24 | $1.9M | $-32.7M | ||
| Q3 24 | $7.8M | $-40.9M | ||
| Q2 24 | $1.5M | $-46.0M | ||
| Q1 24 | $7.9M | $-56.0M |
自由现金流率NRCRGNX
| Q4 25 | 17.2% | -174.0% | ||
| Q3 25 | 29.4% | -189.9% | ||
| Q2 25 | -12.2% | -232.8% | ||
| Q1 25 | 10.9% | 36.6% | ||
| Q4 24 | 5.2% | -154.2% | ||
| Q3 24 | 21.8% | -168.9% | ||
| Q2 24 | 4.3% | -206.2% | ||
| Q1 24 | 22.4% | -358.5% |
资本支出强度NRCRGNX
| Q4 25 | 3.2% | 1.7% | ||
| Q3 25 | 10.4% | 1.7% | ||
| Q2 25 | 8.8% | 1.8% | ||
| Q1 25 | 8.9% | 1.2% | ||
| Q4 24 | 12.0% | 5.1% | ||
| Q3 24 | 4.5% | 1.3% | ||
| Q2 24 | 15.0% | 2.1% | ||
| Q1 24 | 11.7% | 3.6% |
现金转化率NRCRGNX
| Q4 25 | 3.99× | — | ||
| Q3 25 | 3.34× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.15× | 5.53× | ||
| Q4 24 | 0.97× | — | ||
| Q3 24 | 1.66× | — | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | 1.89× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NRC
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
